Fred Alger Management released its fourth-quarter 2025 investor letter for the Alger Weatherbie Specialized Fund, focusing on small and mid-cap companies with growth potential. The US equity market surged 2.7%, driven by corporate earnings, Fed’s interest rate easing, and positive trade policy developments. The Fund’s Class A shares underperformed the Russell 2500 Growth Index.

Highlighting Glaukos Corporation (NYSE: GKOS), Alger Weatherbie Specialized Fund noted the company’s focus on ophthalmic therapies. Glaukos reported strong Q3 results, with revenue growth of 37% driven by its glaucoma product. The FDA approved its corneal health product, Epioxa, with positive pricing expectations. Shares gained 22.99% in the last 52 weeks.

Glaukos Corporation (NYSE: GKOS) was held by 35 hedge fund portfolios in Q3 2025, up from 26 in the previous quarter. The company reported net sales of $133.5 million in Q3 2025, showing 38% growth on a reported basis. While acknowledging Glaukos’ potential, Alger Weatherbie Specialized Fund sees greater upside potential in certain AI stocks.

For more on Glaukos Corporation (NYSE: GKOS) and top medical device stocks to invest in, visit Insider Monkey’s articles. Check out hedge fund investor letters for more insights. Interested investors can explore the best and worst Dow stocks for the next 12 months and 10 unstoppable stocks that could double your money.

Read more at Yahoo Finance: What Makes Glaukos (GKOS) a Good Investment?